Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: Results from the Progredir Cohort.

Silvia Maria de Oliveira TitanGabriela VenturiniKallyandra PadilhaAlessandra C GoulartPaulo A LotufoIsabela J BensenorJose E KriegerRavi I ThadhaniEugene P RheeAlexandre C Pereira

Published in: PloS one (2019)

Our results identify specific metabolites related to hard outcomes in a CKD population. These findings point to the need of further exploration of these metabolites as biomarkers in CKD and the understanding of the underlying biological mechanisms related to the observed associations.

Keyphrases

chronic kidney disease
end stage renal disease
ms ms
mass spectrometry
cardiovascular events
type diabetes
risk factors
coronary artery disease
metabolic syndrome
skeletal muscle
drug induced